Clinical trial
Phase III/Seroquel SR Bipolar Depression Monotherapy - US
NCT00422214 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00422214 |
|---|---|
| Title | Phase III/Seroquel SR Bipolar Depression Monotherapy - US |
| Official title | A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel SR®) Sustained-Release as Monotherapy in Adult Patients With Acute Bipolar Depression |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Affective Psychosis, Bipolar, Depression, Manic-Depressive Psychosis, Psychoses, Manic-Depressive |
| Intervention type | Drug |
| Interventions | Quetiapine fumarate (Seroquel) SR |
| Enrollment | 400 |
| Start date | Dec 1, 2006 |
| Completion | Jun 1, 2007 |
| First posted | Jan 15, 2007 |
| Last update posted | Mar 25, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: